JP7278708B2 - 赤血球内に包摂されたアルギニンデイミナーゼ並びにそれらの癌及びアルギナーゼ-1欠損の治療における使用 - Google Patents
赤血球内に包摂されたアルギニンデイミナーゼ並びにそれらの癌及びアルギナーゼ-1欠損の治療における使用 Download PDFInfo
- Publication number
- JP7278708B2 JP7278708B2 JP2017254383A JP2017254383A JP7278708B2 JP 7278708 B2 JP7278708 B2 JP 7278708B2 JP 2017254383 A JP2017254383 A JP 2017254383A JP 2017254383 A JP2017254383 A JP 2017254383A JP 7278708 B2 JP7278708 B2 JP 7278708B2
- Authority
- JP
- Japan
- Prior art keywords
- arginine
- red blood
- adi
- arginase
- arginine deiminase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims description 172
- 108010082340 Arginine deiminase Proteins 0.000 title claims description 154
- 102100021723 Arginase-1 Human genes 0.000 title claims description 42
- 101710129000 Arginase-1 Proteins 0.000 title claims description 40
- 230000007812 deficiency Effects 0.000 title claims description 35
- 238000011282 treatment Methods 0.000 title description 36
- 206010028980 Neoplasm Diseases 0.000 title description 32
- 201000011510 cancer Diseases 0.000 title description 17
- 239000000725 suspension Substances 0.000 claims description 82
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 28
- 241000204028 Mycoplasma arginini Species 0.000 claims description 24
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 11
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 9
- 229930024421 Adenine Natural products 0.000 claims description 9
- 229960000643 adenine Drugs 0.000 claims description 9
- 230000004071 biological effect Effects 0.000 claims description 3
- 239000011550 stock solution Substances 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 description 66
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 66
- 235000009697 arginine Nutrition 0.000 description 66
- 239000000243 solution Substances 0.000 description 66
- 102000004190 Enzymes Human genes 0.000 description 60
- 108090000790 Enzymes Proteins 0.000 description 60
- 238000000034 method Methods 0.000 description 60
- 210000004369 blood Anatomy 0.000 description 49
- 239000008280 blood Substances 0.000 description 49
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 40
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 38
- 229930064664 L-arginine Natural products 0.000 description 38
- 235000014852 L-arginine Nutrition 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 37
- 239000000047 product Substances 0.000 description 33
- 238000005534 hematocrit Methods 0.000 description 31
- 239000000203 mixture Substances 0.000 description 31
- 238000011534 incubation Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 27
- 230000002950 deficient Effects 0.000 description 25
- 239000008188 pellet Substances 0.000 description 25
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 102000004452 Arginase Human genes 0.000 description 23
- 108700024123 Arginases Proteins 0.000 description 23
- 238000003860 storage Methods 0.000 description 23
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 229910021529 ammonia Inorganic materials 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 16
- 229960001031 glucose Drugs 0.000 description 16
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 229960002173 citrulline Drugs 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000009089 cytolysis Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 12
- 235000013477 citrulline Nutrition 0.000 description 12
- 230000002934 lysing effect Effects 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 230000033115 angiogenesis Effects 0.000 description 10
- 238000000502 dialysis Methods 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 230000003204 osmotic effect Effects 0.000 description 10
- 239000008103 glucose Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 208000034318 Argininemia Diseases 0.000 description 8
- 238000011740 C57BL/6 mouse Methods 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 230000029142 excretion Effects 0.000 description 8
- 201000011286 hyperargininemia Diseases 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 206010040070 Septic Shock Diseases 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 235000020905 low-protein-diet Nutrition 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000036303 septic shock Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 229960001603 tamoxifen Drugs 0.000 description 7
- 206010062695 Arginase deficiency Diseases 0.000 description 6
- 206010020575 Hyperammonaemia Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 239000003761 preservation solution Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229960001855 mannitol Drugs 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 201000006347 Intellectual Disability Diseases 0.000 description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000819 hypertonic solution Substances 0.000 description 4
- 229940021223 hypertonic solution Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 239000000644 isotonic solution Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 4
- 229960003104 ornithine Drugs 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000007971 pharmaceutical suspension Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000004143 urea cycle Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000204003 Mycoplasmatales Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000000187 Abnormal Reflex Diseases 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 description 2
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000006593 Urologic Neoplasms Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 101150088826 arg1 gene Proteins 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 206010020745 hyperreflexia Diseases 0.000 description 2
- 230000035859 hyperreflexia Effects 0.000 description 2
- 239000000815 hypotonic solution Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102100020775 Adenylosuccinate lyase Human genes 0.000 description 1
- 108700040193 Adenylosuccinate lyases Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101710191958 Amino-acid acetyltransferase Proteins 0.000 description 1
- 101710185938 Amino-acid acetyltransferase, mitochondrial Proteins 0.000 description 1
- 206010001939 Aminoaciduria Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 108700040066 Argininosuccinate lyases Proteins 0.000 description 1
- 102100020999 Argininosuccinate synthase Human genes 0.000 description 1
- 101150025804 Asl gene Proteins 0.000 description 1
- 108010070255 Aspartate-ammonia ligase Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100026422 Carbamoyl-phosphate synthase [ammonia], mitochondrial Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000204946 Halobacterium salinarum Species 0.000 description 1
- 101000784014 Homo sapiens Argininosuccinate synthase Proteins 0.000 description 1
- 101000855412 Homo sapiens Carbamoyl-phosphate synthase [ammonia], mitochondrial Proteins 0.000 description 1
- 101000586212 Homo sapiens Mitochondrial ornithine transporter 1 Proteins 0.000 description 1
- 101000983292 Homo sapiens N-fatty-acyl-amino acid synthase/hydrolase PM20D1 Proteins 0.000 description 1
- 101000861263 Homo sapiens Steroid 21-hydroxylase Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 1
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100030108 Mitochondrial ornithine transporter 1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102100032618 N-acetylglutamate synthase, mitochondrial Human genes 0.000 description 1
- -1 NH3 ions Chemical class 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241001223182 Pseudomonas plecoglossicida Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 206010037649 Pyogenic granuloma Diseases 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000037340 Rare genetic disease Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000013557 cerebral hemisphere cancer Diseases 0.000 description 1
- 201000008860 cerebrum cancer Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- FSEUPUDHEBLWJY-HWKANZROSA-N diacetylmonoxime Chemical compound CC(=O)C(\C)=N\O FSEUPUDHEBLWJY-HWKANZROSA-N 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013017 sartobind Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 201000008425 spastic quadriplegia Diseases 0.000 description 1
- 208000031409 spastic quadriplegic cerebral palsy Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 208000030954 urea cycle disease Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
・この酵素が細菌由来でアレルギー反応を誘導し得る
・アルギニンデイミナーゼにより触媒される反応の産物がシトルリン及びアンモニアである
・シトルリンは変換されてアルギニンに戻り得る(図1の尿素サイクル参照)及び
・アンモニアはアルギナーゼ-1欠損の関係で問題が有り、患者は高アンモニア血症の症状を有する。
アルギニンデイミナーゼ
「アルギニンデイミナーゼ」は、「ADI」とも表記し、
本願において「医薬組成物」又は「治療用組成物」は、患者に適切に投与された場合所望の治療的効果を誘導できる化合物又は組成物を意味する。
本発明の発明者らは、赤血球内に包摂されたアルギニンデイミナーゼを含有する医薬組成物が、例えば用量8ml/kgで投与したとき、アルギナーゼ欠損マウスにおいて血中L-アルギニンレベルを投与後3日で73%も低下させることを示した。当業者は、これらの結果が本発明の組成物及び本発明の懸濁物が、アルギナーゼ-1欠損の治療に使用され得ることを示すものと理解する。血清アルギニンのレベルの増大は、治療される対象又は患者の臨床的症状に直接関連するからである。
-乳癌、
-神経芽腫(Gong H. et al., Int. J. Cancer 2003, 106: 723-8)、
-白血病(Gong H. et al. Leukemia 2000, Vol. 14, 826-9; Noh E.J. et al., Int. J. Cancer 2004, 112: 502-8)
の一つである。
本発明の組成物は、好ましくは、所望の治療的効果を生じるように予め決定された計算された量の活性材料を含有する体積で包装され、又は提供される。当業者は、投与すべき組成物の体積又は用量が、投与を想定する哺乳類の状態(例えば体重、年齢、性別及び健康状態、存在する場合併用療法、治療の頻度等)、投与の方式及び製剤の種類等に依存することを理解し得る。
赤血球は、上記「医薬組成物」の項目で記載したように取得され得る。
1-ヘマトクリットレベル65%以上、1~8℃で、赤血球のペレットを等張液中に懸濁する工程、
2-温度1~8℃で冷却した低張溶解溶液とヘマトクリットレベル65%以上の赤血球の懸濁物を、透析装置、例えばコイル又は透析カートリッジ(カートリッジが好ましい)に通す、溶解手順、
3-温度1~8℃で、包摂する酵素(特に事前に作製した溶液中)を、溶解の前又は溶解中に、前記懸濁物中に、好ましくはゆっくり添加することによる、包摂手順、及び
4-より高い温度、特に30~42℃で、等張又は高張、有利には高張溶液の存在下で実施される、再封手順。
1-ヘマトクリットレベル65%以上、1~8℃で、赤血球のペレットを等張液中に懸濁する工程、
2-この同じペレットからの赤血球の試料から浸透圧脆弱性を測定する工程、
3-温度1~8℃で冷却した低張溶解溶液とヘマトクリットレベル65%以上の赤血球の懸濁物を、透析装置、例えばコイル又は透析カートリッジ(カートリッジが好ましい)に通す、溶解手順;溶解パラメーターは先に測定した浸透圧脆弱性に従い調整される;特に、測定された浸透圧脆弱性に依存して、透析装置に赤血球懸濁物を通す流速が調整され、又は溶解溶液の浸透圧が調整される;及び
4-温度1~8℃で、包摂する酵素(特に事前に作製した溶液中)を、溶解の前又は溶解中に、前記懸濁物中に、好ましくはゆっくり添加することによる、包摂手順;及び
5-より高い温度、特に30~42℃で、等張又は高張、有利には高張溶液の存在下で実施される、再封手順。
(a)赤血球内に酵素を包摂する工程、当該工程は、赤血球を低張培地に接触させる工程(赤血球の膜に穴を空ける)、有効成分と接触させる工程(それを赤血球内に侵入させる)、特に等張又は高張、有利には高張培地を用いて赤血球を再封する工程を含む、
(b)酵素を包摂した赤血球及びオスモル濃度280 mOsmol/kg以上、特に約280~約380 mOsmol/kg、好ましくは約290~約330 mOsmol/kgの溶液を含有する懸濁物又はペレットを取得又は調製する工程、
(c)工程(b)のペレット又は懸濁物をそのまま又はインキュベーション溶液を添加した後、オスモル濃度280 mOsmol/kg以上、特に約280~約380 mOsmol/kg、好ましくは約290~約330 mOsmol/kgで、30分以上、特に1時間以上インキュベーションする工程、
(d)工程(c)のインキュベーションした懸濁物の液体培地を除去する工程、
(e)工程(d)で得た赤血球を、懸濁物を患者に注射できる溶液、特に懸濁物を患者に注射できる保存溶液に懸濁する工程。
高生産性クローン株の生産及び単離
マイコプラズマ・アルギニニ由来ADIの天然の配列(GenBank: X54141)は、遺伝子コードがE.コリとM.アルギニニ間で相違するため、幾つかのコドンを改変することによって最適化した(コードC1124-ADM-02の新しいプラスミドを作製した)。精製プロセスは、Misawa and coll. (Misawa, S. et al, 1994, J. of Biotechno. 36, 1994, 145-155)に記載されているものを、若干改変している。即ち、細菌生成HMS174 (DE3) T1R株を、JM101株に代えて使用した。他の改変は下記に示す。
生産は、バッチ培地を入れた発酵器中で、撹拌しながら、プレカルチャー2から圧力及びpHを調整して、最適密度0.05で行われた。光学密度(600nm)が100になるまで増殖相(37℃)が行われ、発現誘導は32℃で1mMのIPTGを培養培地中に添加することによって行われた。細胞沈殿物が2つの相において誘導後26~27時間後に回収され:細胞ブロスは、500kDa中空ファイバーを通した後に5~10倍に濃縮され、細胞ペレットは15900×gで回収され、-20℃で保存された。
ADIは、包摂体(IB)として生産された。細胞ペレットを溶解緩衝剤中に懸濁して、細胞を破壊した。そして破壊した細胞を洗浄してIBを回収し、IBを-20℃で保存した。
酵素の特異的活性は、実施例2に記載するように、生産されたシトルリンを測定することによって決定された。タンパク質含量は、280nmの吸光度を読み取って決定された。純度はSDS-PAGEによって決定された。オスモル濃度はオスモメーター(Micro-Osmometer Loser Type 15)を用いて測定された。ADIの生産されたバッチの主要な特徴を下記表2に纏める。
このアッセイは、以下の2段階の反応に基づく(Boyde and Rahmatullah, 1980, Analytical Biochemistry, vol 107, p 424-431):
-第一に、L-アルギニンが、ADIによって、シトルリンとアルギニンに変換される。
-第二に、ジアセチルモノオキシム、塩化鉄(III)、チオセミカルバジド、硫酸及び塩酸の存在下、シトルリンが、530nmで読み取り可能な色付きの発色団に変換される。
C57BL/6マウス(Charles River)の全血を1000×g、10分間4℃で遠心分離して、血漿及び軟膜を除去した。赤血球を0.9%NaCl(v:v)で3回洗浄した。凍結ADIを融解し、この赤血球懸濁物に添加して、ADIの初期含量2~7mg/mL、ヘマトクリット65%の最終懸濁物を得た。
終了した産物のADI活性は、水溶液中のADIの外的校正範囲に対して実施例4に記載された方法を用いてアッセイされた。これらの結果は、終了した産物中のADI活性がRBC中に導入された酵素の量に伴い増大し、良好な安定性を維持しながら終了した産物1mlあたり2mgのADIを容易に包摂し得ることを示す。ERY-ADIマウス最終産物の6つの異なるバッチ(ERY-ADI-1~6)の主要な特徴を、表3に示す。
赤血球中に保持されたADIと上清中のADIの活性のアッセイは、L-アルギニンからADIによって生成されるNH3の測定に基づく。NH3イオンは、Roche Diagnostics (11877984)により販売されるキットに従い、グルタミン酸デヒドロゲナーゼ(GLDH)の酵素作用によって間接的にアッセイされた。
ERY-ADI6マウス産物はCFSE(蛍光)で標識され、C57BL/6マウス中に静脈内投与された。各タイムポイント(D0 + 15分, D0 + 6時間, D1, D2, D5, D9, D13及びD16)で3頭のマウスを屠殺し、血液をヘパリンリチウムチューブ上に回収し、暗黒下4℃で薬物動態を判定した。全血中のCFSEで標識された赤血球細胞の比率を、フローサイトメトリー法によって判定した。5マイクロリットルの全血試料を0.5%BSAを含有するPBS1ml中に希釈し、各試料を3回通した(FL-1; cytometer FC500, Beckman Coulter中で10,000細胞のカウントを行った)。ADIを担持した赤血球の生存率の評価は、T0+15分でのCFSEで標識したADIを担持する赤血球の比率(100%対照)に異なるタイムポイントでCFSEで標識したADIを担持する赤血球の比率を足して得られた。各時間における様々な得られたパーセンテージは図2に描画したグラフ中に示され、従って図2は、時間に対する循環中のADIを担持する赤血球の比率を示している。
ADI酵素を包摂した赤血球の産物ERY-ADI6を、8ml/kgの用量でC57BL/6マウス中に静脈内注射した。各タイムポイント(D0 + 15分, D0 + 6時間, D1, D2, D5, D9, D13及びD16)で3頭のマウスを屠殺し、血液をヘパリンリチウムチューブ上に回収し、4℃で血漿L-アルギニンレベルを判定した。
アルギナーゼ欠損マウス(詳細はSin et al, 2013, PLOS One, vol. 8 (11))を用いてインビトロ試験を行った。これらのマウスはアルギナーゼ1活性を欠くため、ヒトで通常見られる高アルギニン血症の重度の病理生化学的側面を呈する。高アルギニン血症(又はアルギナーゼ欠損)は、タモキシフェンの5回注射によって引き起こされる。血中アルギニン濃度は、最後のタモキシフェン注射後数日で上昇し始める。このマウスモデルにおいてマウス産物ERY-ADI4が血中L-アルギニンレベルを低下させる効果を実証するため、最後のタモキシフェン注射の7日後のアルギナーゼ欠損マウス15頭にERY-ADI4(4及び8mL/kg)及びモックロード赤血球(8mL/kg)を静脈内注射した。3つの産物を注射した日(D1)及びその2日後(D3)に、血液を回収した。このインビボ試験の結果を、図4及び図5並びに下記表4に示す。
マウス産物ERY-ADIがこのマウスモデルにおいて血中L-アルギニンレベルを低下する効果を確認するため、実施例7の通りにタモキシフェンで処理したマウスに対し、第二の試験を行った。ERY-ADI産物を、最後のタモキシフェン注射の3日後に静脈内注射した。ERY-ADIの1又は2回の静脈内投与(8mL/kg)が予定された(それぞれ群2及び3)。対照群には、遊離状態のADI酵素を投与した(群4)。アルギナーゼ活性を担持するマウスからなる第二の対照群は、この試験の部分であった(群1)。
白血球枯渇ヒトRBC1袋(Etablissement francais du sangより提供)を、0.9%NaClで3回洗浄した。アルギニンデイミナーゼ(ADI)溶液をゆっくり溶かし、RBC懸濁物に添加して、ヘマトクリット60%、ADI含量3又は5mg/mLの最終濃度のRBC懸濁物を得た。懸濁物をホモジナイズし、流速90mL/hで血液透析器にロードし、30mOsmol/kgの低張溶液に対して透析した。そして懸濁物を高張溶液で再封して、30分4℃でインキュベーションした。0.9%NaCl、0.2%グルコースで3回洗浄した後、懸濁物を保存溶液AS3(NaCl, NaH2PO4, クエン酸 Na-クエン酸, アデニン及びグルコース。オスモル濃288 mOs/kg及びpH 5.88)中に取り上げた。得られた産物を、0日、1日及びx日で特定した。血液学的特性は、獣医学的オートマトン(Sysmex, PocH-100iV)を用いて得られた。
0日での6つの終了した産物の血液学的及び生化学的特徴を、下記表に示す:3つは3mg/mLのADI濃度で製造し、3つは5mg/mLの濃度で製造したもので、これらは透析前のRBC懸濁物に関連して表される。全てのERY-ADI産物は、同一のADIのバッチを用いて調製されている。インビトロ安定性は、0日、1日及び7日で評価されている。
赤血球(RBC)中に閉じ込められたアルギニンデイミナーゼ(ADI; EC番号3.5.3.6)は、Erytechの所有するERYCAPS技術プラットフォームを用いて得られる。赤血球内に治療的酵素を閉じ込める技術は、効果的な長期に作用する治療的活性を低毒性で提供し得る。
Claims (9)
- 赤血球中に包摂されたアルギニンデイミナーゼ及び医薬として許容されるビヒクルを含有する、アルギナーゼ-1欠損の治療に用いるための医薬組成物。
- オスモル濃度270~350 mOsm/lの懸濁物である、請求項1に記載の医薬組成物。
- 前記医薬として許容されるビヒクルが、NaCl及びアデニンを含有する保存溶液である、請求項1又は2のいずれか1項に記載の医薬組成物。
- 前記アルギニンデイミナーゼがM.アルギニニ(M.arginini)由来である、請求項1~3のいずれか1項に記載の医薬組成物。
- 前記アルギニンデイミナーゼが、配列番号1のアミノ酸配列を含むもの、又はその変異体若しくは断片であり、前記変異体又は断片が、配列番号1のアミノ酸配列を有するアルギニンデイミナーゼの生物活性を保持しており、前記変異体又は断片が、配列番号1のアミノ酸配列と90%以上同一であるアミノ酸配列を含む、請求項1~4のいずれか1項に記載の医薬組成物。
- 前記アルギニンデイミナーゼが補因子を必要としない、請求項5に記載の医薬組成物。
- 前記包摂されたアルギニンデイミナーゼの濃度が0.1~7 mg/mlである、請求項1~6のいずれか1項に記載の医薬組成物。
- 体積10~250mlの用量で包装される、請求項1~7のいずれか1項に記載の医薬組成物。
- 患者用の1回用量の包摂されたアルギニンデイミナーゼの量が、当該患者の体重1kgあたり包摂されたアルギニンデイミナーゼ0.01~500 mg/kgである、請求項8に記載の医薬組成物。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18733316.6A EP3675896A1 (en) | 2017-08-31 | 2018-06-29 | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
AU2018322679A AU2018322679B2 (en) | 2017-08-31 | 2018-06-29 | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
PCT/EP2018/067679 WO2019042628A1 (en) | 2017-08-31 | 2018-06-29 | ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY |
KR1020207005870A KR20200044822A (ko) | 2017-08-31 | 2018-06-29 | 적혈구 내부에 캡슐화된 아르기닌 데이미나제 및 암 및 아르기나제-1 결핍 치료에서 이의 용도 |
MX2020002222A MX2020002222A (es) | 2017-08-31 | 2018-06-29 | Arginina deiminasa encapsulada dentro de eritrocitos y su uso en el tratamiento de cancer y la deficiencia de arginasa-1. |
IL272879A IL272879B2 (en) | 2017-08-31 | 2018-06-29 | Dorsalized arginine deiminase within erythrocytes and their use in the treatment of cancer and arginase-1 deficiency |
RU2020108594A RU2773220C2 (ru) | 2017-08-31 | 2018-06-29 | Аргининдеиминаза, инкапсулированная в эритроциты, и их применение при лечении рака и недостаточности аргиназы-1 |
SG11202001461RA SG11202001461RA (en) | 2017-08-31 | 2018-06-29 | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
US16/643,431 US11273210B2 (en) | 2017-08-31 | 2018-06-29 | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
CA3073471A CA3073471A1 (en) | 2017-08-31 | 2018-06-29 | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
US17/689,002 US20220193208A1 (en) | 2017-08-31 | 2022-03-08 | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17306122.7 | 2017-08-31 | ||
EP17306122.7A EP3449935A1 (en) | 2017-08-31 | 2017-08-31 | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019043931A JP2019043931A (ja) | 2019-03-22 |
JP2019043931A5 JP2019043931A5 (ja) | 2022-07-27 |
JP7278708B2 true JP7278708B2 (ja) | 2023-05-22 |
Family
ID=59859010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017254383A Active JP7278708B2 (ja) | 2017-08-31 | 2017-12-28 | 赤血球内に包摂されたアルギニンデイミナーゼ並びにそれらの癌及びアルギナーゼ-1欠損の治療における使用 |
Country Status (9)
Country | Link |
---|---|
US (2) | US11273210B2 (ja) |
EP (2) | EP3449935A1 (ja) |
JP (1) | JP7278708B2 (ja) |
KR (1) | KR20200044822A (ja) |
AU (1) | AU2018322679B2 (ja) |
CA (1) | CA3073471A1 (ja) |
IL (1) | IL272879B2 (ja) |
MX (1) | MX2020002222A (ja) |
SG (1) | SG11202001461RA (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008538761A (ja) | 2005-04-25 | 2008-11-06 | エリテシュ ファルマ | アルギニンデイミナーゼを含む赤血球 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6062867A (ja) | 1983-09-16 | 1985-04-11 | Hitachi Ltd | 電源回路 |
JPH0235081A (ja) | 1988-07-26 | 1990-02-05 | Agency Of Ind Science & Technol | アルギニン・デイミナーゼおよびその用途 |
JPH0253490A (ja) | 1988-08-16 | 1990-02-22 | Agency Of Ind Science & Technol | アルギニン・デイミナーゼ遺伝子 |
JP2900279B2 (ja) | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
US5372942A (en) | 1992-02-10 | 1994-12-13 | Coriell Institute For Medical Research | Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent |
US5804183A (en) | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
AU2001275810A1 (en) | 2000-07-27 | 2002-02-13 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
EP2295560A1 (en) * | 2009-09-14 | 2011-03-16 | RWTH Aachen University | Directed evolution of arginine deiminase for increased activity at physiological pH |
FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
EP3071515A2 (en) | 2013-11-18 | 2016-09-28 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
CN111787941A (zh) * | 2017-12-05 | 2020-10-16 | 艾瑞思有限公司 | 用于治疗精氨酸酶1缺乏症的方法和组合物 |
-
2017
- 2017-08-31 EP EP17306122.7A patent/EP3449935A1/en not_active Withdrawn
- 2017-12-28 JP JP2017254383A patent/JP7278708B2/ja active Active
-
2018
- 2018-06-29 MX MX2020002222A patent/MX2020002222A/es unknown
- 2018-06-29 SG SG11202001461RA patent/SG11202001461RA/en unknown
- 2018-06-29 KR KR1020207005870A patent/KR20200044822A/ko not_active Application Discontinuation
- 2018-06-29 AU AU2018322679A patent/AU2018322679B2/en active Active
- 2018-06-29 IL IL272879A patent/IL272879B2/en unknown
- 2018-06-29 US US16/643,431 patent/US11273210B2/en active Active
- 2018-06-29 CA CA3073471A patent/CA3073471A1/en active Pending
- 2018-06-29 EP EP18733316.6A patent/EP3675896A1/en active Pending
-
2022
- 2022-03-08 US US17/689,002 patent/US20220193208A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008538761A (ja) | 2005-04-25 | 2008-11-06 | エリテシュ ファルマ | アルギニンデイミナーゼを含む赤血球 |
Non-Patent Citations (5)
Title |
---|
Ballantyne, L. L. et al.,Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency,Molecular Genetics and Metabolism Reports,2016年,Vol.9,p.54-60,doi:10.1016/j.ymgmr.2016.10.003 |
Gay, F. et al.,Arginine deiminase loaded in erythrocytes: a promising formulation for L-arginine deprivation therapy in cancers. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR,Cancer Research,2016年,Vol.76, No.14 Suppl,Abstract No.4812,doi: 10.1158/1538-7445.AM2016-4812 |
Park, I. S. et al.,Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth,British Journal of Cancer,2003年,Vol.89, No.5,p.907-914,doi:10.1038/sj.bjc.6601181 |
Sin, Y. Y. et al.,Arginase-1 deficiency,Journal of Molecular Medicine (Berlin, Germany),2015年,Vol.93, No.12,p.1287-1296,doi:10.1007/s00109-015-1354-3 |
Takaku, H. et al.,In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini,International Journal of Cancer,1992年,Vol.51, No.2,p.244-249,doi:10.1002/ijc.2910510213 |
Also Published As
Publication number | Publication date |
---|---|
EP3449935A1 (en) | 2019-03-06 |
MX2020002222A (es) | 2020-07-22 |
JP2019043931A (ja) | 2019-03-22 |
RU2020108594A3 (ja) | 2021-09-09 |
EP3675896A1 (en) | 2020-07-08 |
AU2018322679A1 (en) | 2020-03-05 |
SG11202001461RA (en) | 2020-03-30 |
US20200254074A1 (en) | 2020-08-13 |
CA3073471A1 (en) | 2019-03-07 |
IL272879A (en) | 2020-04-30 |
IL272879B1 (en) | 2023-10-01 |
AU2018322679B2 (en) | 2022-03-10 |
US11273210B2 (en) | 2022-03-15 |
IL272879B2 (en) | 2024-02-01 |
US20220193208A1 (en) | 2022-06-23 |
KR20200044822A (ko) | 2020-04-29 |
RU2020108594A (ru) | 2021-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210008114A1 (en) | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and, a non-phosphate plp precursor | |
EP3025728B1 (en) | Method for purifying prokaryotic phenylalanine ammonia-lyase variants | |
Yew et al. | Erythrocytes encapsulated with phenylalanine hydroxylase exhibit improved pharmacokinetics and lowered plasma phenylalanine levels in normal mice | |
JP7240743B2 (ja) | ホモシスチン尿症を処置するためのシスタチオニンβ-シンターゼ酵素 | |
EP3007715B1 (en) | Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof | |
KR20180005249A (ko) | 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법 | |
KR101535791B1 (ko) | 개량형 이듀로네이트-2-설파타제 및 이의 용도 | |
WO2021239046A1 (zh) | rhFGF21融合蛋白、编码其的多核苷酸、包含其的组合物及其用途 | |
JP7278708B2 (ja) | 赤血球内に包摂されたアルギニンデイミナーゼ並びにそれらの癌及びアルギナーゼ-1欠損の治療における使用 | |
WO2019042628A1 (en) | ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY | |
RU2773220C2 (ru) | Аргининдеиминаза, инкапсулированная в эритроциты, и их применение при лечении рака и недостаточности аргиназы-1 | |
WO2024088213A1 (en) | Combination to induce specific immune tolerance | |
AU2024203333A1 (en) | Formulations comprising recombinant acid alpha-glucosidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20180126 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220714 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20220714 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230206 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230206 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230213 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230418 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230510 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7278708 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |